Drug intelligence / Profile preview

RBM-002

Development stage: Unknown
Lead developer: Ribomic
Modality: RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

RBM-002 is an investigational drug developed by Ribomic. It is a nucleic acid aptamer, similar in modality to other Ribomic pipeline candidates, and is being explored for ophthalmic indications. While detailed public information on its mechanism of action or specific molecular target is limited as of June 2025, it follows the company's focus on aptamer-based therapeutics for diseases with high unmet medical need. The primary developer and likely manufacturer is Ribomic.

Brand names: RBM-002RBM002RBM 002
Other names: RBM-002RBM002RBM 002

Targets

FGF2

Beyond the preview

Go deeper on RBM-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBM-002.

Explore the full profile